TherapeuticsMD (NASDAQ:TXMD) Shares Pass Below 50 Day Moving Average – Should You Sell?

TherapeuticsMD, Inc. (NASDAQ:TXMD) passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $2.06 and traded as low as $2.01. TherapeuticsMD shares last traded at $2.06, with a volume of 25,510 shares trading hands.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of TherapeuticsMD from a “sell (d-)” rating to a “sell (d+)” rating in a report on Wednesday, August 12th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

TherapeuticsMD Stock Up 1.5%

The company has a market capitalization of $23.83 million, a PE ratio of 103.00 and a beta of 0.61. The company has a 50-day moving average price of $2.06 and a two-hundred day moving average price of $2.12.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings data on Tuesday, August 11th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($6.12) by $6.13. The company had revenue of $0.87 million for the quarter, compared to analyst estimates of $19.77 million. TherapeuticsMD had a negative return on equity of 1.09% and a negative net margin of 6.64%.

Institutional Investors Weigh In On TherapeuticsMD

Hedge funds and other institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC boosted its position in shares of TherapeuticsMD by 51.5% in the first quarter. Renaissance Technologies LLC now owns 146,200 shares of the company’s stock valued at $295,000 after acquiring an additional 49,700 shares during the period. Tejara Capital Ltd grew its stake in TherapeuticsMD by 1.9% during the fourth quarter. Tejara Capital Ltd now owns 350,852 shares of the company’s stock valued at $572,000 after acquiring an additional 6,649 shares in the last quarter. Finally, Citadel Advisors LLC increased its holdings in TherapeuticsMD by 125.5% during the 3rd quarter. Citadel Advisors LLC now owns 34,273 shares of the company’s stock worth $36,000 after acquiring an additional 19,073 shares during the period. 30.74% of the stock is currently owned by institutional investors.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.